21 Sep 2019
CSCO 2019: Association Between Hand-Foot Skin Reaction (HFSR) and Survival Benefit of Fruquintinib in FRESCO Trial
THE LANCET :
FRESCO-2, a global Phase III study of fruquintinib in refractory metastatic colorectal cancer
Learn More
THE LANCET HAEMATOLOGY:
ESLIM-01 Phase III Study: Sovleplenib for primary immune thrombocytopenia patients in China
Learn More
THE LANCET Respiratory Medicine
Savolitinib Phase IIIb confirmatory study in treatment-naive METex14 NSCLC patients in China
Learn More
2024 Full Year Financial Results
Learn More
Latest News
24 Nov 2021HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor TherapyRead more 8 Nov 2021HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual MeetingRead more 1 Nov 2021HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combination with PD-L1 Inhibitor IMFINZI® in Patients with MET-Driven Advanced Papillary Renal Cell CarcinomaRead more
28 Oct 2021HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thrombocytopenia in ChinaRead more 29 Sep 2021HUTCHMED Highlights Oral Presentations at 2021 Chinese Society of Clinical Oncology Annual MeetingRead more 29 Sep 2021HUTCHMED Announces Closing of Divestment of Non-Core OTC Joint VentureRead more 21 Sep 2021HUTCHMED Initiates SURTORI-01, a Phase III Trial of SULANDA® in Combination with TUOYI® in the Treatment of Advanced Neuroendocrine Carcinoma in ChinaRead more See all
2000
FOUNDED
HCM
NASDAQ &
LONDON AIM
LONDON AIM
13
HKEX
>20
NOVEL DRUG CANDIDATES
CREATED BY IN-HOUSE
DISCOVERY ENGINE
CREATED BY IN-HOUSE
DISCOVERY ENGINE
4
APPROVED & MARKETED
PRODUCTS IN CHINA
PRODUCTS IN CHINA
1
APPROVED & MARKETED
PRODUCT IN THE US, EU & JAPAN
PRODUCT IN THE US, EU & JAPAN
~40
CLINICAL TRIALS WORLDWIDE
INCLUDING 13+ REGISTRATION STUDIES
INCLUDING 13+ REGISTRATION STUDIES
>150,000
PATIENTS TREATED BY
OUR NOVEL MEDICINES
OUR NOVEL MEDICINES
OUR SCIENCE
Our core research and development philosophy is to take a holistic approach and treat cancer and immunological diseases through multiple modalities and mechanisms. We have taken a science-focused approach to develop highly selective, potent and well-tolerated cancer therapies that are deliberately engineered to improve drug exposure and reduce off-target toxicities.
FOLLOW HUTCHMED ON SOCIAL MEDIA
